| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 57.71 | 0.5% | 9.5% |
| Total Income | 57.71 | 0.5% | 9.5% |
| Expenditure | 57.33 | 3.3% | 11.4% |
| PBT | -0.51 | 82.3% | 828.6% |
| Net Profit | -0.55 | 81.3% | 2650.0% |
| OPM | 0.66% | 3.90pp | 1.68pp |
| NPM | -0.95% | 4.17pp | 0.92pp |
| EPS | 0.00 | 100.0% |
Cerus Corporation Announces Third Quarter 2026 Financial Results
03 Nov 2026 · 3 Nov, 2:42 am
Summary
Cerus Corporation announced its financial results for the third quarter ended September 30, 2026, reporting total revenue of $64.0 million, a 6% increase year-over-year, driven by a 10% rise in product revenue to $57.7 million. The company highlighted significant growth in its INTERCEPT Fibrinogen Complex (IFC) volumes and announced positive topline results from its Phase 3 RedeS trial for the INTERCEPT Blood System for red blood cells. Management expressed increased confidence as they approach year-end, citing continued growth from their IFC business and core platelet franchise.
Key Highlights
- 1
Cerus Corporation reported third quarter 2026 total revenue of $64.0 million, a 6% increase year-over-year.
- 2
Product revenue for the third quarter of 2026 reached $57.7 million, marking a 10% year-over-year growth.
- 3
The company achieved approximately 80% growth in INTERCEPT Fibrinogen Complex (IFC) volumes compared to the prior year period.
- 4
Positive topline results from the Phase 3 RedeS trial of the INTERCEPT Blood System for red blood cells were announced.
- 5
Operating cash flow for the third quarter of 2026 was $3.0 million, an increase from the prior year period.
- 6
Non-GAAP adjusted EBITDA for the third quarter of 2026 was positive $5.7 million, compared to positive $5.0 million in the prior year period.
Management Comments
Vivek Jayaraman
Our solid performance in Q3 builds upon a strong first half of 2026 and increases our confidence as we approach year-end. Continued growth from our IFC business, core platelet franchise and international INT 200 rollout strengthens our foundation as we work to establish INTERCEPT as the global standard of care. The positive topline results we announced today from the Phase 3 RedeS study mark an important milestone as we drive toward extending the benefits of pathogen reduction to red cell transfusions. I’m pleased with our progress and grateful to my colleagues who remain focused on delivering for our customers and the patients they serve.
Informational and educational content only. Not investment advice.